Xiaowei W Su1, Wint Nandar1, Elizabeth B Neely1, Zachary Simmons2, James R Connor1. 1. Department of Neurosurgery, Penn State College of Medicine, Mailcode H110, 500 University Drive, Hershey, Pennsylvania, 17033, USA. 2. Department of Neurology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Abstract
INTRODUCTION: HMG-CoA reductase inhibitors (statins) and H63D HFE polymorphism may modify amyotrophic lateral sclerosis (ALS). We hypothesized that statins worsen phenotype in ALS mice, dependent on HFE genotype. METHODS: Mice harboring SOD1(G93A) heterozygous for H67D Hfe (homologous to human H63D HFE) were administered simvastatin and/or coenzyme Q10, and were allowed to reach end stage. Disease progression was measured by grip strength. A separate group of animals was administered simvastatin and euthanized at the symptomatic 120-day time-point. Mitochondria from gastrocnemius muscle and lumbar spine were analyzed. RESULTS: Simvastatin and H67D Hfe accelerated disease progression. Simvastatin decreased survival. Coenzyme Q10 did not rescue statin-induced effects. Statins did not alter mitochondrial protein levels. CONCLUSIONS: Statins and Hfe genotype alter disease course in the ALS mouse model. Because the H63D HFE polymorphism is present in 30% of patients with ALS, studying disease progression in patients who receive statins, stratified for HFE genotype, may guide therapy. Muscle Nerve, 2016 Muscle Nerve 54: 284-291, 2016.
INTRODUCTION: HMG-CoA reductase inhibitors (statins) and H63D HFE polymorphism may modify amyotrophic lateral sclerosis (ALS). We hypothesized that statins worsen phenotype in ALSmice, dependent on HFE genotype. METHODS:Mice harboring SOD1(G93A) heterozygous for H67D Hfe (homologous to human H63D HFE) were administered simvastatin and/or coenzyme Q10, and were allowed to reach end stage. Disease progression was measured by grip strength. A separate group of animals was administered simvastatin and euthanized at the symptomatic 120-day time-point. Mitochondria from gastrocnemius muscle and lumbar spine were analyzed. RESULTS:Simvastatin and H67D Hfe accelerated disease progression. Simvastatin decreased survival. Coenzyme Q10 did not rescue statin-induced effects. Statins did not alter mitochondrial protein levels. CONCLUSIONS: Statins and Hfe genotype alter disease course in the ALSmouse model. Because the H63D HFE polymorphism is present in 30% of patients with ALS, studying disease progression in patients who receive statins, stratified for HFE genotype, may guide therapy. Muscle Nerve, 2016 Muscle Nerve 54: 284-291, 2016.
Authors: Adrian Israelson; Nir Arbel; Sandrine Da Cruz; Hristelina Ilieva; Koji Yamanaka; Varda Shoshan-Barmatz; Don W Cleveland Journal: Neuron Date: 2010-08-26 Impact factor: 17.173
Authors: Fatima Ali-Rahmani; Patricia S Grigson; Sang Lee; Elizabeth Neely; James R Connor; Cara-Lynne Schengrund Journal: Neurobiol Aging Date: 2013-12-25 Impact factor: 4.673
Authors: Veronique E Miron; Simone P Zehntner; Tanja Kuhlmann; Samuel K Ludwin; Trevor Owens; Timothy E Kennedy; Barry J Bedell; Jack P Antel Journal: Am J Pathol Date: 2009-04-06 Impact factor: 4.307
Authors: Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano Journal: Biomedicines Date: 2022-05-10
Authors: James C Dodge; Elizabeth H Jensen; Jinlong Yu; S Pablo Sardi; Allison R Bialas; Tatyana V Taksir; Dinesh S Bangari; Lamya S Shihabuddin Journal: J Neurosci Date: 2020-10-13 Impact factor: 6.167
Authors: Marc G Weisskopf; Joseph Levy; Aisha S Dickerson; Sabrina Paganoni; Maya Leventer-Roberts Journal: Am J Epidemiol Date: 2022-06-27 Impact factor: 5.363
Authors: Fardin Nabizadeh; Mohammad Balabandian; Amir Mohammad Sharafi; Ali Ghaderi; Mohammad Reza Rostami; Abdorreza Naser Moghadasi Journal: Acta Neurol Belg Date: 2021-07-28 Impact factor: 2.471